Polyvalent immunoglobulin significantly attenuated the formation of IL-1β in Escherichia coli-induced sepsis in pigs

Immunobiology

Volumn 218, Issue 5, 2013, Pages 683-689

  Barratt Due, Andreas ^a   Sokolov, Andrey ^a   Gustavsen, Alice ^a   Hellerud, Bernt Christian ^a   Egge, Kjetil ^a   Pischke, Soeren Erik ^a   Lindstad, Julie Katrine ^a   Pharo, Anne ^a   Castellheim, Albert ^a,b   Thorgersen, Ebbe Billmann ^a   Mollnes, Tom Eirik ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

Cytokines; IgGAM; Inflammasome; IVIG; Sepsis

Indexed keywords

CD11 ANTIGEN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; BINDING AFFINITY; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG MECHANISM; ESCHERICHIA COLI; GRAM NEGATIVE SEPSIS; HEMODYNAMICS; NEUTROPHIL COUNT; NONHUMAN; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SWINE;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; BIOLOGICAL MARKERS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HEMODYNAMICS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; PROTEIN BINDING; SEPSIS; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875671259     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.08.268     Document Type: Article

References (35)

1. Alejandria M.M., Lansang M.A., Dans L.F., Mantaring J.B. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst. Rev. 2000, CD001090.
2. Aukrust P., Froland S.S., Liabakk N.B., Muller F., Nordoy I., Haug C., Espevik T. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994, 84:2136-2143.
3. Basta M., Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 1994, 94:1729-1735.
4. Basta M., Van G.F., Luccioli S., Billings E.M., Vortmeyer A.O., Baranyi L., Szebeni J., Alving C.R., Carroll M.C., Berkower I., Stojilkovic S.S., Metcalfe D.D. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 2003, 9:431-438.
5. Bayry J., Lacroix-Desmazes S., Carbonneil C., Misra N., Donkova V., Pashov A., Chevailler A., Mouthon L., Weill B., Bruneval P., Kazatchkine M.D., Kaveri S.V. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003, 101:758-765.
6. Berlot G., et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J. Crit. Care 2012, 27:167-171.
7. Boldt J. Do plasma substitutes have additional properties beyond correcting volume deficits?. Shock 2006, 25:103-116.
8. Castellheim A., Thorgersen E.B., Hellerud B.C., Pharo A., Johansen H.T., Brosstad F., Gaustad P., Brun H., Fosse E., Tonnessen T.I., Nielsen E.W., Mollnes T.E. New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs. Scand. J. Immunol. 2008, 68:75-84.
9. Dellinger R.P., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2008, 34:17-60.
10. Hartung H.P., Mouthon L., Ahmed R., Jordan S., Laupland K.B., Jolles S. Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin. Exp. Immunol. 2009, 158(Suppl 1):23-33.
11. Hellman J., Loiselle P.M., Zanzot E.M., Allaire J.E., Tehan M.M., Boyle L.A., Kurnick J.T., Warren H.S. Release of Gram-negative outer-membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to Escherichia coli J5. J. Infect. Dis. 2000, 181:1034-1043.
12. Hoffman J.N., Fertmann J.M., Vollmar B., Laschke M.W., Jauch K.W., Menger M.D. Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia. Shock 2008, 29:133-139.
13. Horvath G.L., Schrum J.E., De Nardo C.M., Latz E. Intracellular sensing of microbes and danger signals by the inflammasomes. Immunol. Rev. 2011, 243:119-135.
14. Jackson S.K., Parton J., Barnes R.A., Poynton C.H., Fegan C. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur. J. Clin. Invest. 1993, 23:540-545.
15. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 2001, 345:747-755.
16. Kreymann K.G., de H.G., Nierhaus A., Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit. Care Med. 2007, 35:2677-2685.
17. Lissner R., Struff W.G., Autenrieth I.B., Woodcock B.G., Karch H. Efficacy and potential clinical applications of Pentaglobin, an IgM-enriched immunoglobulin concentrate suitable for intravenous infusion. Eur. J. Surg. Suppl. 1999, 17-25.
18. Marshall J.C., Deitch E., Moldawer L.L., Opal S., Redl H., van der Poll T. Preclinical models of shock and sepsis: what can they tell us?. Shock 2005, 24(Suppl. 1):1-6.
19. Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., Lambris J.D. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002, 100:1869-1877.
20. Mollnes T.E., Hogasen K., Hoaas B.F., Michaelsen T.E., Garred P., Harboe M. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties. Scand. J. Immunol. 1995, 41:449-456.
21. Mouthon L., Kaveri S.V., Spalter S.H., Lacroix-Desmazes S., Lefranc C., Desai R., Kazatchkine M.D. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin. Exp. Immunol. 1996, 104(Suppl. 1):3-9.
22. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 2008, 26:513-533.
23. Perel P., Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst. Rev. 2011, CD000567.
24. Remick D.G. Pathophysiology of sepsis. Am. J. Pathol. 2007, 170:1435-1444.
25. Rieben R., Roos A., Muizert Y., Tinguely C., Gerritsen A.F., Daha M.R. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 1999, 93:942-951.
26. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., Peterson E., Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001, 345:1368-1377.
27. Saetre T., Lindgaard A.K., Lyberg T. Systemic activation of coagulation and fibrynolysis in a porcine model of serogroup A streptococcal shock. Blood Coagul. Fibrinolysis 2000, 11:433-438.
28. Shankar-Hari M., Spencer J., Sewell W.A., Rowan K.M., Singer M. Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit. Care 2012, 16:206.
29. Stehr S.N., Knels L., Weissflog C., Schober J., Haufe D., Lupp A., Koch T., Heller A.R. Effects of IGM-enriched solution on polymorphonuclear neutrophil function, bacterial clearance, and lung histology in endotoxemia. Shock 2008, 29:167-172.
30. Thorgersen E.B., Hellerud B.C., Nielsen E.W., Barratt-Due A., Fure H., Lindstad J.K., Pharo A., Fosse E., Tonnessen T.I., Johansen H.T., Castellheim A., Mollnes T.E. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J. 2010, 24:712-722.
31. Trautmann M., Held T.K., Susa M., Karajan M.A., Wulf A., Cross A.S., Marre R. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin. Exp. Immunol. 1998, 111:81-90.
32. Tugrul S., Ozcan P.E., Akinci O., Seyhun Y., Cagatay A., Cakar N., Esen F. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Crit. Care 2002, 6:357-362.
33. Van B.W. Evaluation of hemoconcentration from hematocrit measurements. J. Appl. Physiol. 1972, 32:712-713.
34. Werdan K. Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr. Opin. Crit. Care 2001, 7:354-361.
35. Ziegler E.J., McCutchan J.A., Fierer J., Glauser M.P., Sadoff J.C., Douglas H., Braude A.I. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 1982, 307:1225-1230.